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Vascular proteasomeSystemic knockout of adipose triglyceride lipase (ATGL), the pivotal enzyme of triglyceride lipolysis, results in a
murine phenotype that is characterized by progredient cardiac steatosis and severe heart failure. Since cardiac
and vascular dysfunction have been closely related in numerous studies we investigated endothelium-
dependent and -independent vessel function of ATGL knockout mice. Aortic relaxation studies and Langendorff
perfusion experiments of isolated hearts showed that ATGL knockout mice suffer from pronounced micro- and
macrovascular endothelial dysfunction. Experiments with agonists directly targeting vascular smooth muscle
cells revealed the functional integrity of the smooth muscle cell layer. Loss of vascular reactivity was restored
~50% upon treatment of ATGL knockout mice with the PPARα agonist Wy14,643, indicating that this phenome-
non is partly a consequence of impaired cardiac contractility. Biochemical analysis revealed that aortic endothe-
lial NO synthase expression and activity were signiﬁcantly reduced in ATGL deﬁciency. Enzyme activity was fully
restored in ATGL mice treated with the PPARα agonist. Biochemical analysis of perivascular adipose tissue
demonstrated that ATGL knockout mice suffer from perivascular inﬂammatory oxidative stress which occurs
independent of cardiac dysfunction andmight contribute to vascular defects. Our results reveal a hitherto unrec-
ognized link between disturbed lipid metabolism, obesity and cardiovascular disease.
© 2014 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license
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Adipose triglyceride lipase (ATGL) has been identiﬁed as key en-
zymeofmammalian lipolysis, i.e. the hydrolytic cleavage of triglycerides
into free fatty acids and diacylglycerols. ATGL is predominantly
expressed in adipose tissue but found to a lesser extent in a variety of
other tissues and organs, including kidney, skeletal muscle, and heart.
Studies with ATGL knockout (AKO) mice [1] revealed the systemic im-
portance of this lipase. Deletion of the gene encoding for ATGL resulted
in a phenotype with massive neutral lipid accumulation in multiple tis-
sues and cell types. ATGL-deﬁcient mice suffer from an overall defect in
energy homeostasis, defective thermogenesis, and severe cardiomyopa-
thy, the latter leading to premature death of the animals [1].
In the myocardium ATGL deﬁciency has been shown to cause age-
dependent increase of myocyte lipid droplets in number and size and,
in parallel, progressive development of ventricular hypertrophy [1].
Langendorff perfusion experiments of isolated hearts extended
these ﬁndings, showing that contractile and microvascular responses
to ß-adrenergic stimulation by norepinephrine are drastically impaired
in ATGL-deﬁcient hearts [2]. Chronic treatment of AKO mice with
the peroxisome proliferator receptor α (PPARα) agonist Wy14,643the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).
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markedly downregulated in ATGL-deﬁcient hearts [3], suggesting
that impaired PPARα signaling essentially contributes to the observed
cardiac phenotype.
A close relationship between chronic heart failure and endothelial
dysfunction has been established in laboratory animals and humans
(for review, see [4]), and the severity of endothelial dysfunction has
been proposed as prognostic factor for the long-term outcome of pa-
tients suffering from heart failure [5,6]. It is assumed that impaired
left-ventricular function in heart failure signiﬁcantly reduces shear
stress-induced formation of endothelium-derived NO and consequent
NO-dependent dilation of vascular smoothmuscle cells. Conversely, im-
paired peripheral vasodilation leads to higher systemic vascular resis-
tance and consequent increased cardiac workload, which aggravates
cardiac dysfunction. In addition, reduced myocardial perfusion due to
compromised vasodilator capacity of coronary arteries partially contrib-
utes to ventricular dysfunction.
Recently, Hirano and colleagues reported about a male patient ho-
mozygous for a point mutation in the ATGL gene suffering from severe
congestive heart failure and undergoing cardiac transplantation [7].
Biopsies of the explanted heart showed triglycerides accumulating in
atherosclerotic lesions of coronary arteries. In addition, cytoplasmatic
lipid storage was observed within endothelial cells and foam cells of
the intima as well as within smooth muscle cells of the media. In view
of this human correlate and concerning the severe cardiac impairments
inmurine ATGL deﬁciencywe aimed to studymicro- andmacrovascular
function in this animal model.
2. Theory
AKO mice which represent a rodent model of human neutral lipid
storage disease with myopathy (NLSDM) [8] suffer from severe cardiac
dysfunction due to ectopic triglyceride accumulation in the heart ﬁnally
leading to premature death of the animals [1]. This study has been
designed (i) to investigate vessel function of this animal model with re-
spect to its cardiac phenotype and (ii) to test for a potential role of
perivascular adipose tissue (PVAT) in maintenance of vascular tone.
3. Materials and methods
3.1. Mice and experimental groups
Homozygous AKO mice on a C57BL/6 background [1] and age-
matched WT littermates were used for this study. After weaning, ani-
mals received standard laboratory mouse chow and water ad libitum.
Animals subjected to the PPARα agonist treatment protocol were fed
control diet mixed with 0.1% Wy14,643 (Cayman Chemical, Ann
Arbor, MI, USA) for 3 weeks starting at ~7 weeks of age, as previously
described [3]. Mice were housed in approved cages and kept on a regu-
lar 12 h dark/light cycle. Animals were sacriﬁced at ~10 weeks of age.
All animals received care in accordancewith the Austrian law on exper-
imentation with laboratory animals (last amendment, 2012), which is
based on the US National Institutes of Health guidelines. The protocol
was approved by the Austrian FederalMinistry for Science and Research
(BMWF-66.007/0001-ll/3b/2014).
3.2. Isometric tension vasomotor studies
In a ﬁrst series of vasomotor studies, the response of aortic vessels to
endothelium-dependent and -independent relaxing agents was tested
in the absence of perivascular adipose tissue (PVAT). Therefore, de-
scending aortas were removed, carefully cleaned from surrounding
PVAT and cut into rings of ~3 mm width and mounted in 5 ml-organ
baths ﬁlled with oxygenated Krebs–Henseleit solution (118.4 mM
NaCl, 25 mM NaHCO3, 4.7 mM KCl, 1.2 mM KH2PO4, 2.5 mM CaCl2,
1.2 mM MgCl2, 10.1 mM D-glucose; pH 7.4). Care was taken to retainthe endothelium for relaxation experiments. Tissues were equilibrated
for 60 min by repeatedly adjusting tension to 0.5 g and changing
the bath solution. Then, maximal contractile activity was determined
with a depolarizing solution of 100 mM K+. Rings that did not elicit
adequate and stable contraction to high K+ were considered to be
damaged and omitted from the study. After washout, tissues were
precontracted with the thromboxane mimetic 9,11-dideoxy-9α,11α-
epoxy-methanoprostaglandin F2α (U 46619) to an equivalent level of
~1.2 g total tone (i.e. ~90% contracture obtained with high K+). After
reaching a stable contraction, cumulative concentration–response
curves were established with acetylcholine (ACh; 1 nM–10 μM) or
2,2-diethyl-1-nitroso-oxyhydrazine (DEA/NO; 1 nM–10 μM; Enzo Life
Sciences AG, Lausen, Switzerland). The contractile force corresponding
to each agonist concentration was recorded and expressed as percent
of precontraction (=baseline). To test for the role of NADPH oxidase-
derived superoxide, aortic rings were incubated for 30 min in the pres-
ence of either gp91ds-dat [9] (50 μM; piChem, Graz, Austria) or a com-
bination of cell-permeable superoxide dismutase (PEG-SOD; 100 U/ml)
and catalase (PEG-cat; 500 U/ml) prior to addition of ACh or DEA/NO. In
a second series of experiments, the role of PVAT was investigated in
paired aortic rings prepared either with or without PVAT. Removal of
PVAT from one half of the aorta was randomly assigned to avoid any
systematic effects due to the repeated use of similar aortic segments.
The equilibration period was followed by repeated challenge with 100
mM K+ solution until the contractile response became reproducible.
After determination of the contractile response to increasing isotonic
K+ solutions (15, 30, 60, 100mM), cumulative concentration–response
curves to U46619 (1 nM–300 nM) were established. The response of
each agonist dose was normalized to the effect of 100 mM K+. In
a third series of experiments, relaxation to ACh (1 nM–10 μM) or
DEA/NO (1 nM–10 μM) was measured in precontracted aortic rings in
the absence and presence of PVAT using the protocol described above.3.3. Langendorff perfusion of isolated hearts
Mice were euthanized by inhalation of CO2 as recommended by the
Austrian law on experimentation with laboratory animals. Hearts were
rapidly excised and arrested in ice-cold Krebs–Henseleit buffer. After
cannulation of the aorta with a 20 gauge needle, retrograde perfusion
was established at a constant ﬂow of 20 ml/min/g wet weight with a
modiﬁed Krebs–Henseleit bicarbonate buffer, pH 7.4 (118 mM NaCl,
25 mM NaHCO3, 1.2 mM KH2PO4, 4.8 mM KCl, 1.2 mM MgSO4,
1.25 mM CaCl2, 11 mM D-glucose) using the ISO-HEART perfusion sys-
tem (Hugo Sachs Elektronik, March-Hugstetten, Germany) as previous-
ly described [10]. The perfusate was ﬁltered through a 5 μm ﬁlter before
infusion and continuously gassedwith carbogen (95%O2, 5% CO2). Heart
temperature, measured with a physitemp probe (Physitemp Instru-
ments, Clifton, NJ), wasmaintained at 37 °C throughout the experiment.
After removal of the left auricle, a tiny ﬂuid-ﬁlled balloon, made of a
small square of a polyethylene ﬁlm, was inserted into the left ventricle
and connected to a pressure transducer via a 4 F biluminal monitoring
catheter (Vygon, Aachen, Germany). The following cardiac parameters
were monitored using the PLUGSYS data acquisition and control setup
for circulatory studies (Hugo Sachs Elektronik, March-Hugstetten,
Germany) and recorded using a PowerLab system (ADInstruments
Ldt, Hastings, UK): left-ventricular end-diastolic pressure, peak left-
ventricular systolic pressure, left-ventricular developed pressure,
maximum rate of rise and fall of left ventricular pressure, heart rate
(obtained from the pressure signal using a differentiator and heart
rate module, respectively) and, as a measure for coronary vessel func-
tion, coronary perfusion pressure (CPP; via a second pressure transduc-
er attached to the aortic cannula). After establishing stable perfusion
conditions (30 min equilibration), bradykinin (BK; 1 nM–3 μM) was
added via a sideline to the perfusion medium and changes in CPP
recorded.
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The microvascular endothelial cell line (MyEnd) was established
frommouse hearts by immortalizationwith polyomamiddle T oncogene
as described previously [11]. The retrovirus packing cell line GP+E−86
[12] was kindly provided by B. Engelhardt (Theodor Kocher Institute,
Bern, Switzerland).MyEnd cells were immunopositive for the endotheli-
al markers vascular endothelial cadherin and cluster of differentiation 31
(CD31). Cells were grown in Dulbecco's Modiﬁed Eagle Medium
(DMEM; Life Technologies, Karlsruhe, Germany) supplemented with
100 U/ml penicillin, 0.1 mg/ml streptomycin, 1.25 μg/ml amphotericin
B, and 10% (v/v) heat-inactivated fetal calf serum (PPA Laboratories
GmbH, Vienna, Austria) in humidiﬁed atmosphere (95% O2/5% CO2) at
37 °C. Passages 1–5 were used for experiments. MyEnd cells formed
monolayers of highly elongated cells frequently organized into whirl-
like formations. The overall cell shape and growth pattern resembled
that of primary cultures of microvascular endothelial cells from
brain and skin [13,14] and differed signiﬁcantly from the typical cobble-
stone pattern formed by macrovascular endothelial cells from various
sources [15].
3.5. Incorporation and release of [3H]oleate
MyEnd cells seeded on 12-well plates were incubated for 20 h
in DMEM (low glucose), containing 400 μM oleic acid complexed
with fatty acid-free bovine serum albumin (BSA) and esteriﬁed [3H]
oleic acid (~5 ∗ 105 cpm; Hartmann Analytic GmbH, Braunschweig,
Germany) as radiolabeled tracer. After removal of medium, cells
were washed with phosphate-buffered saline (PBS). Lipids were
extracted with ice-cold hexane/isopropanol (3:2) and the solvent was
evaporated under a gentle stream of nitrogen. Lipids were resuspended
in chloroform, transferred onto TLC silica gel 60 plates (Merck,
Darmstadt, Germany) and separated using hexane/diethylether/acetic
acid (70:29:1) as solvent. Plates were stained with iodine and mono-,
di-, and triglycerides were identiﬁed by comparison with an analytical
lipid standard mix (Sigma, Vienna, Austria). Radioactive spots contain-
ing triglycerides were excised and radioactivity determined by liquid
scintillation counting. Results were expressed as cpm/mg protein. In
another series of experiments, release of [3H]oleic acid, which had
been incorporated into intracellular triglycerides, was induced by addi-
tion of 2% fatty acid-free BSA. After incubation for 4 h, extraction and
separation of lipid products and quantiﬁcation of [3H]oleic acid were
performed as described above. To measure incorporation of glucose-
derived carbon into the cellular triglyceride pool MyEnd cells were
challenged with [14C]glucose (0.1 μCi/ml) in the absence and presence
of 400 μM non-labeled oleic acid for 20 h. Extraction, separation, and
quantiﬁcation of triglycerides were performed as described above.
3.6. Real-time and conventional PCR
Total RNA was isolated from cells and homogenized tissues
using the GenElute™ Mammalian Total RNA Miniprep Kit (Sigma,
Vienna, Austria) including DNAse (Sigma, Vienna, Austria) treatment of
samples. RNAwas transcribed to cDNAusing theHighCapacity cDNARe-
verse Transcription Kit (Applied Biosystems, Vienna, Austria). Real-time
PCR analysis was performed with ~30 ng cDNA using TaqMan® Univer-
sal PCRMasterMix and pre-designed TaqMan®Gene Expression Assays
for endothelial NO synthase (eNOS; Mm00435204_m1), NADPH oxi-
dase 2 subunit (NOX2; Mm00432775_m1), tumor necrosis factor α
(TNFα; Mm00443258_m1), monocyte chemotactic protein-1 (MCP-1;
Mm00441243_g1), interleukin 6; (IL-6; Mm00446190_m1), heme
oxygenase-1 (HO-1; Mm00516005_m1_F), and SOD-1 (Mm01700393_
g1). Reactionswere carried out on a 7300Real-Time PCR System (Applied
Biosystems, Vienna, Austria). Cycling conditionswere as follows: 2min at
50 °C, 10 min at 95 °C, 40 cycles of 15 s at 95 °C and for 1 min at 60 °C.
Data were analyzed according to the 2−ΔΔCt method using cyclophilin(Mm00835365_g1) as reference gene. Lack of ampliﬁcation was veriﬁed
in no-template controls. Splicing of XBP1mRNAwas analyzed by conven-
tional PCR using the following primers TTACGAGAGAAAACTCATGGCC
(fwd); GGGTCCAAGTTGTCCAGAATGC (rev) [16]. Ampliﬁcation products
were separated by agarose gel electrophoresis (3%).
3.7. Western blot analysis
Tissues were homogenized in 5–10 volumes of RIPA lysis buffer
(Sigma, Vienna, Austria) containing 0.5 mM ethylenediaminetetra-
acetic acid (EDTA), protease and phosphatase inhibitors (Complete™;
PhosSTOP™; Roche, Vienna, Austria) using a glass potter Elvehjem
homogenizer. Homogenates prepared from PVAT were centrifuged for
10 min at 1000 g (4 °C) and lipid-free infranatants were collected and
used for Western blot analysis. Endothelial cells were harvested and
homogenized by repeated sonication on ice. Denatured samples
(10–30 μg) were separated by SDS-PAGE (8% or 10% gels) and trans-
ferred onto nitrocellulose membranes. After blocking with Tris-
buffered saline containing 0.1% (v/v) Tween-20 and 5% nonfat dry
milk or 5% BSA for 1 h (ambient temperature) membranes were
incubated overnight at 4 °C with antibodies against ATGL (1:1000;
Cell Signaling through New England Biolabs, Frankfurt, Germany),
eNOS (1:2000; BD Transduction Laboratories, Heidelberg, Germany),
Ser1177phospho-eNOS (1:1000; BD Transduction Laboratories),
vasodilator-stimulated phosphoprotein (VASP; 1:1000; Cell Signaling),
Ser239phospho-VASP (1:1000; Calbiochem through VWR, Vienna,
Austria), NOX2 (1:5000; BD Transduction Laboratories), p67phox
(1:5000; BD Transduction Laboratories), p47phox (1:1000; Novus
Biologicals, Cambridge, UK), NOX4 (1:1000; Abcam, Cambridge, UK),
SOD-1 (1:1000; Santa Cruz Biotechnology, Inc., Heidelberg, Germany),
ubiquitin (1:4000; Dako, Vienna, Austria), proteasome 20S core sub-
unit (1:1000; Enzo Life Sciences AG, Lausen, Switzerland), galectin-3
(Mac-2; 1:10,000; Cedarlane through Szabo-Scandic, Vienna, Austria),
α-tubulin (1:10,000; Sigma, Vienna, Austria), binding immunglobulin
protein (BIP; 1:1000; Cell Signaling), heat shock protein 90 (Hsp90;
1:1000; Cell Signaling), inositol-requiring enzyme 1α (IRE-1α;
1:1000; Cell Signaling), and glyceraldehyde-3-phosphate dehydroge-
nase (GAPDH; 1:50,000; Sigma). After incubation of membranes with
respective horseradish peroxidase-conjugated anti-rabbit or anti-
mouse IgG (1:5000) immunoreactive bands were visualized by
chemiluminescence using ChemiGlow™ (Biozym, Vienna, Austria)
and quantiﬁed densitometrically using the E.A.S.Y. Win 32 software
(Herolab, Vienna, Austria). Puriﬁed human eNOS expressed in Pichia
pastoris was used as standard [17].
3.8. Determination of NOS activity
Aortas were homogenized in 0.15 ml of a 50 mM triethanolamine/
HCl buffer (pH 7.4) containing 1% (v/v) ß-mercaptoethanol, 10 mM 3-
[(3-cholamidopropyl)dimethyl-ammonio]-1-propanesulfonate, 0.5
mM EDTA and Complete™ using a glass potter Elvehjem homogenizer.
Homogenates were centrifuged at 10,000 g for 10 min at 4 °C. Superna-
tants were assayed for NOS activity as conversion of [3H]L-arginine
(~105 cpm; Perkin Elmer, Vienna, Austria) to [3H]L-citrulline as previ-
ously described [18]. Results were corrected for enzyme-deﬁcient
blanks and recovery of L-citrulline. NOS activity of intact MyEnd
cells was determined as previously described [19]. Cells were incu-
bated for 10min at 37 °C in 1 ml of 50mM Tris–HCl (pH 7.4) contain-
ing 100 mM NaCl, 5 mM KCl, 3 mM CaCl2, and 1 mMMgCl2 with [3H]
L-arginine (~106 cpm) in the absence and presence of ACh (10 μM) or
ionomycin (1 μM). Thereafter, cells were washed with 1 ml chilled
nominally Ca2+-free incubation buffer and lysed in 10 mM HCl for 1 h
at per ambient temperature. Aliquots of 0.1mlwere removed for deter-
mination of incorporated radioactivity. Sampleswere adjusted to pH5.0
with 0.2 M sodium acetate buffer, containing 10 mM L-citrulline
(pH 13.0). [3H]L-citrulline was separated from [3H]L-arginine by cation
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scintillation counting. Cellular NOS activity is expressed as % of
[3H]L-citrulline formed from incorporated [3H]L-arginine.
3.9. Determination of NADPH oxidase activity
MyEnd cells seeded on 6-well plates were homogenized in 0.5 ml
PBS containing Complete™ by repeated sonication on ice. Homogenates
containing 50–100 μg of protein were incubated in PBS, containing
diethylenetriamine pentaacetic acid (0.1 mM) at 37 °C for 30 min in
the absence or presence of the NADPH oxidase inhibitor gp91ds-dat
(50 μM) [9]. Subsequently, NADPH (0.3 mM) and lucigenin (5 μM)
were added [20] and lucigenin-derived chemiluminescence (CL) was
measured every 10 s for 5min using a TriCarb® 2100TR Liquid Scintilla-
tion Counter (Perkin Elmer, Vienna, Austria). Results were corrected for
protein-deﬁcient blanks and expressed as cpm/mg protein.
3.10. Tissue triglyceride hydrolase assay
Lipolytic activities of aorta andwhite adipose tissue (WAT)were de-
termined using the triglyceride hydrolase assay as described recently
[21]. Tissueswere homogenized in a solution containing 0.25M sucrose,
1mMEDTA, 1mMdithiothreitol, and Complete™ (pH 7.0) using a glass
potter Elvehjem homogenizer, and homogenates were centrifuged at
20,000 g for 30 min at 4 °C. Infranatants were collected and aliquots
(~30 μg) incubated with 0.15 mM [3H]triolein (~106 cpm; Perkin
Elmer, Vienna, Austria) as radioactive tracer. Samples were incubated
in a total volume of 0.2 ml for 1 h at 37 °C and reactions terminated
by addition of 3.25 ml methanol/chloroform/heptane (10:9:7) and
1 ml of 0.1 M K2CO3/0.1 M H3BO3 (pH 10.5). Samples were centrifuged
at 800 g for 20 min at an ambient temperature and 1 ml aliquots of the
upper phase were collected. Radioactivity was determined by liquid
scintillation counting.
3.11. Adipose H2O2 formation
H2O2 release from PVAT was measured using 10-acetyl-3,7-
dihydroxyphenoxazine (Ampliﬂu) according to themanufacturer's pro-
tocol of Amplex® Red Hydrogen Peroxide/Peroxidase Assay Kit (Life
Technologies, Vienna, Austria). Freshly isolated PVAT from WT and
AKO mice was cut into two pieces of 5–15 mg. Tissue was incubated
in a mixture of 750 μl Krebs–Ringer buffer (145 mM NaCl, 4.86 mM
KCl, 5.70 mM NaH2PO4, 0.54 mM CaCl2, 1.22 mM MgCl2, 5.5 mM
glucose; pH 7.4) and 150 μl reaction buffer (10 mM Ampliﬂu and
10 U/ml horseradish peroxidase in Krebs–Ringer buffer) for 1 h at
37 °C in the absence and presence of catalase (250 U/ml). H2O2
release into the incubation buffer was quantiﬁed by the horseradish
peroxidase-catalyzed oxidation of 10-acetyl-3,7-dihydroxy-phenoxazine
to the ﬂuorescent product resoruﬁn at excitation and emission maxima
of 571 nm and 585 nm, respectively. PVAT was homogenized in Krebs–
Ringer buffer using a glass potter Elvehjem homogenizer and protein
concentrations were measured with the Thermo Scientiﬁc Pierce BCA™
Protein Assay Kit.
3.12. Scanning electron microscopy
Anesthetized mice were pinned in supine position onto a wax plate,
the chest was opened by sternotomy, the ascending aorta was exposed
and a ligature from thread was placed around its proximal portion.
Thereafter, a hole was punched into the apex of the left ventricle and
a bluntly grinded veinﬂow catheter G21 was introduced via the hole
into the ascending aorta under stereomicroscopic control using a
micromanipulator. The cannula was placed slightly distally to the liga-
ture, the latter was closed, the left atrium was incised and rinsing of
the circulatory system with 0.9% NaCl solution was started (ﬂow rates:
70–99 ml/h; volume of perfusate: 7.5–10 ml; duration of rinsing:6–8 min). When clear efﬂux escaped the left atrium, perfusion with
buffered 2.5% glutaraldehyde in 0.1 M sodium cacodylate buffer
(pH 7.35) was started via the same route (ﬂow rates: 70–99 ml/h; vol-
umeperfused: 10ml; duration ofﬁxation: 4–7 min). Then, thoracic aor-
tas were excised under binocular control and immersed under fresh
ﬁxative for 2 h at room temperature. After twowashes for 30min aortas
were transferred into 70% ethanol and stored overnight at 4 °C. Then,
aortas were cut into three segments which were cut longitudinally
into two halves with razor blades while submerged in 70% ethanol.
Specimens were dehydrated in a graded series of ethanol (80%, 90%,
and 96% for 30 min each; 100I, 100II, and 100III for 20 min each) and
critical point dried via carbon dioxide. Dry specimens were mounted
onto specimen stubs by colloidal silver, evaporated with carbon and
gold, sputteredwith gold, and examined in the scanning electronmicro-
scope XL-30 (FEI, Eindhoven, The Netherlands) at an accelerating volt-
age of 20 kV. If necessary, brightness and contrast of micrographs
taken were adjusted by the Adobe Photoshop 7.0 software.
3.13. Immunohistochemistry and H&E staining
Thoracic aortas were formalin-ﬁxed, parafﬁn-embedded, and sec-
tioned. Sections were either stained with hematoxylin and eosin
(H&E) according to a standard protocol or labeled for immunohisto-
chemistry by incubatingwith anti-mouse CD31 (1:50; Thermo Scientif-
ic, Vienna, Austria) or anti-mouse α-smooth muscle actin (α-SMA;
1:50; Abcam, Cambridge, UK) for 1 h at ambient temperature. Subse-
quently, specimens were incubated with HRP Polymers (TL-060-HL;
Thermo Scientiﬁc, Vienna, Austria) or the AEC system (Dako, Vienna,
Austria) for visualization of CD31 and α-SMA, respectively. Analysis
was performed with a Nikon Eclipse 80i microscope supplied with
camera and using the NIS-Elements D software.
3.14. Protein quantiﬁcation
Protein concentrations were either measured by the method of
Bradford [22] or with the Thermo Scientiﬁc Pierce BCA™ Protein Assay
Kit (Fisher Scientiﬁc Austria GmbH, Vienna, Austria) using BSA as
standard.
3.15. Statistics
Concentration–response curves established in aortic ring experi-
ments were ﬁtted to a Hill-type model giving estimates of agonist po-
tency (EC50) and efﬁcacy (Emax). Concentration–response curves of
different ring segments from a single animal were averaged and count-
ed as individual experiment. ANOVA with post hoc Bonferroni–Dunne
test was used for comparison between groups using StatView®
(Version 5.0). Experiments performed with aortas, WAT and MyEnd
cells were, unless otherwise indicated, analyzed using the unpaired
Student's t-test. Signiﬁcance was assumed at P b 0.05. Data are present-
ed as mean values ± SEM of n experiments.
4. Results
4.1. Endothelium-dependent vessel function is abolished in ATGL deﬁciency
The vasodilatory potency of the endothelium-dependent agonist
ACh was studied with precontracted aortic rings isolated fromWT and
AKO mice. As shown in Fig. 1A, ACh relaxed WT vessels in a
concentration-dependent manner with an EC50 of 240 ± 70 nM and a
maximal effect of 67 ± 5% relaxation. The effect of ACh was completely
inhibited by the NO synthase (NOS) inhibitor NG-nitro-L-arginine (data
not shown). In contrast to WT vessels, AKO aortas responded only
marginally to ACh (17 ± 3% relaxation). Chronic treatment of AKO
mice with the PPARα agonist Wy14,643 (which restores cardiac con-
tractility [2]) led to a ~50% improved ACh response (42 ± 2% maximal
Fig. 1. ATGL deﬁciency causes severe endothelial dysfunction. (A) Aortic relaxation to ACh was impaired in AKOmice. The relaxant response was partially restored by treatment with the
PPARα agonistWy14,643. Vasorelaxation toDEA/NOwas not affected. (C) Treatmentwith theNADPH oxidase inhibitor gp91ds-dat (50 μM)or a combination of PEG-SOD (100 U/ml) and
PEG-cat (500 U/ml) did not restore the relaxant response to ACh. (D) Neither gp91ds-dat nor PEG-SOD/PEG-cat affected relaxation to DEA/NO. (E) Relaxation of coronary arteries to BK
was severely impaired in ATGL-deﬁcient hearts. (F) The dilatory response of coronary vessels to DEA/NO was not affected. Results represent mean values ± SEM of 5 individual experi-
ments. *P b 0.05 vsWT; §P b 0.05 vs AKO.
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of ACh. As indicated by a preserved response of the rings to the NO
donor DEA/NO (Fig. 1B) and adequate contraction to K+ and to a
thromboxane receptor agonist (see Fig. 5 below), impaired relaxation
to ACh did not involve dysfunction of vascular smooth muscle cells.
Preincubation of aortic rings with either a combination of cell-
permeable PEG-SOD and PEG-cat or the selective peptide inhibitor of
NADPH oxidases, gp91ds-dat, failed to restore the effect of ACh in
ATGL deﬁciency (Fig. 1C). These agents neither affected relaxation toDEA/NO (Fig. 1D), excluding a signiﬁcant role of superoxide-mediated
inactivation of endothelium-derived NO in this experimental setup.
The function ofmicrovascular endothelial cells was tested bymeasuring
CPP of isolated hearts in response to the endothelium-dependent vaso-
dilator BK. While the compound decreased CPP in WT hearts in a
concentration-dependent manner (EC50 = 12 ± 1 nM), the agonist
was ineffective in AKO hearts (Fig. 1E). As observed with aortic rings,
ATGL deﬁciency did not affect microvascular relaxation to the NO
donor DEA/NO (Fig. 1F).
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ATGL has been identiﬁed and characterized in a variety of tissues and
cell types (for review, see [23]), but there is sparse knowledge about
ATGL expression in blood vessels. As shown in Fig. 2A, functionally ac-
tive ATGL was detected in aortic homogenates of WT mice. Protein ex-
pression levels and triglyceride hydrolase activity were ~25% and ~5%,
respectively, of the values measured in WAT of WT mice. Various bio-
chemical parameters of NO signaling were measured in aortas from
WT and genetically modiﬁed mice. Protein expression of eNOS was de-
creased to less than 40% in AKO aortas (Fig. 2B). ATGL deﬁciency had
similar effects on the levels of eNOS phosphorylation at Ser1177
(Fig. 2B) and enzyme activity measured as L-arginine to L-citrulline con-
version (Fig. 2C). Representative Western blots are shown in Fig. 2H.
Treatment of AKO mice with the PPARα agonist Wy14,643 completely
restored NOS activity in vascular preparations (Fig. 2C) indicating that
the observed effect on eNOS is due to cardiac dysfunction. Aortic eNOS
mRNA levels were onlymarginally affected. Albeit therewas a tendency
towards increased levels in ATGL deﬁciency, results did not reach statis-
tical signiﬁcance (Fig. 2D). Phosphorylation of cytoskeleton-associated
VASP at Ser239, which represents a reliable biochemical marker for the
function of the NO/cGMP pathway [24], was abolished in AKO aortas
(Fig. 2E, H). Surprisingly, expression of VASP protein was also signiﬁ-
cantly reduced in ATGL-deﬁcient vessels (Fig. 2E, H). Decreased eNOS
protein expression despite of unchanged mRNA levels suggested that
protein stability was affected in ATGL-deﬁcient vessels. Therefore, we
tested for activation of the proteasome by measuring levels of
ubiquitinated proteins in aortic homogenates [25]. As shown in Fig. 2F,
the total amount of ubiquitinated proteins was signiﬁcantly reducedFig. 2.NO/cGMP signaling is blunted in AKO aortas. (A) ATGL is functionally expressed inWT aorta
aorta vsWAT. (B) Protein expression and Ser1177 phosphorylation of eNOS were signiﬁcantly dec
formation of L-citrulline) was comparably reduced in ATGL deﬁciency. The effect on enzyme
Wy14,643. *P b 0.05 vsWT; §P b 0.05 AKO (untreated) vs AKO (Wy 14,643-treated); n = 4–9. (D
at Ser239were decreased in AKO aortas; *P b 0.05 vsWT; n= 12–14. (F) Aortic expression of ubiqu
tein expressionwas signiﬁcantly increased in aortas of AKOmice; *P b 0.05 vsWT; n=9. (I) Expre
Fig. A, results are expressed relative toWT controls (=1). Data illustrated in Fig. Cwere analyzed
represent mean values ± SEM of n experiments.in ATGL-deﬁcient aortas. Additionally, aortic protein expression of the
20S core protein (which comprises the protease-like catalytic sites of
the 26S proteasome)was increasedmore than 4-fold in ATGL deﬁciency
(Fig. 2G, H), corroborating the hypothesis of enhanced proteasomal
degradation. Aortic mRNA levels of the inﬂammation marker TNFα
were increased nearly 4-fold in ATGL deﬁciency (Fig. 2I).
To test if vascular ER stress is involved in activation of the proteasome
we measured key determinants of the UPR (Fig. S1). The IRE-1/XBP1
branch of the vascular UPR was not signiﬁcantly affected in ATGL de-
ﬁciency. Similarly, protein levels of ER-resident chaperons BIP, PDI,
Hsp90 were not signiﬁcantly altered in aortas of AKO mice.
4.3. Characterization of ATGL-deﬁcient endothelial cells
To investigate the endothelial defect on a cellular level, a model of
microvascular ATGL-deﬁcient endothelial cells was created from AKO
hearts (Fig. 3A) and characterized in terms of NO signaling and related
signaling pathways. Cellular ATGL deﬁciency was conﬁrmed as lack of
mRNA (data not shown) and protein expression (see Fig. 3J for a repre-
sentative Western blot). In ATGL-deﬁcient endothelial cells ~12-fold
higher incorporation of [3H]oleate into triglycerides was observed
as compared to WT cells (Fig. 3B). Moreover, lipolytic breakdown of
[3H]oleate-containing triglycerides was not detected in ATGL-deﬁcient
cells, whereas more than 60% of [3H]oleate-containing triglycerides
were catabolized in WT cells (Fig. 3B). Challenging of cells with
[14C]glucose resulted in signiﬁcantly increased incorporation of
glucose-derived carbon matrix into the cellular triglyceride pool under
both basal (Fig. 3C) and oleate-loaded (data not shown) conditions. In
marked contrast to the effects observed in isolated aortas, expressions. Triglyceride hydrolase activity of aortaswas compared to that ofWAT; n=4–5; *P b 0.05;
reased in AKO aortas; *P b 0.05 vsWT; n = 12–14. (C) Vascular NOS activity (measured as
activity was completely reversed in aortas of AKO mice treated with the PPARα agonist
) Aortic eNOS mRNA levels; n = 5–8. (E) Protein expression and phosphorylation of VASP
itinated proteinswasmarkedly decreased in ATGL deﬁciency. (G) Proteasomal 20S core pro-
ssion of TNFαmRNAwas upregulated in ATGL deﬁciency; *P b 0.05 vsWT;n=4–5. Except in
for statistical signiﬁcance byANOVAusing Student–Newman–Keuls as post hoc test. Data
Fig. 3. Generation of microvascular ATGL-deﬁcient endothelial cells. (A, B) Endothelial cells isolated from AKO hearts showed increased capacity of triglyceride storage, impaired lipolytic
activity, and (C) increased incorporation of glucose-derived carbon into cellular triglycerides. *P b 0.05; AKO vsWT at 20 h; §P b 0.05; WT 20 h vs 24 h; n = 3. (D) mRNA (n= 5–6) and
(E) protein expression of eNOS (n= 6) aswell as (F) basal and stimulated enzyme activity (n= 6–11)were not affected in ATGL-deﬁcient cells. (G) Protein expression of NOX 2 (n= 3)
andNOX4 (n=6) aswell as (H)NADPHoxidase-dependent lucigenin CL (n=3–4)was similar inWT andAKO cells; *P b 0.05; untreated vs gp91ds-dat-treatedWT;#P b 0.05; untreated
vs gp91ds-dat-treated AKO. (I) Expression of ubiquitinated proteins was not affected by endothelial ATGL deﬁciency; n= 5. Expression of NOX2 and NOX4 protein aswell as eNOSmRNA
is presented relative to WT controls (=1). eNOS protein is expressed as μg eNOS per mg total protein using puriﬁed eNOS as standard. eNOS activity is expressed as % of [3H]L-citrulline
formed from incorporated [3H]L-arginine. Data represent mean values ± SEM of n experiments.
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ulated enzyme activity (Fig. 3F) were not affected by ATGL deﬁciency.
To test whether NO availability is compromised in those cells due to
increased formation of reactive oxygen species, cellular superoxide pro-
ductionwasmeasured as lucigenin chemiluminescence and expression
levels of the most abundant endothelial NADPH oxidase isoforms.
Neither protein expression of NOX2 and NOX4 (Fig. 3G) nor superoxide
production (Fig. 3H) was affected. Finally, ubiquitinated protein levels
were identical in WT and ATGL-deﬁcient endothelial cells (Fig. 3I).
These results clearly indicate that at the level of isolated AKO endothe-
lial cells the major characteristics of endothelial dysfunction are no
longer evident.
4.4. Characterization of PVAT
There is increasing evidence suggesting that PVAT modulates blood
vessel function by production and release of various vasoactive sub-
stances (for reviews, see [26,27]). Therefore, we characterized PVAT
associated with thoracic aortas of WT and AKO mice and analyzed
for mRNA and protein expression of different inﬂammatory and
oxidative markers. PVAT wet weight was increased nearly 7-fold in
AKO mice (Fig. 4A, B). Adipose mRNA levels of the inﬂammation
markers TNFα (Fig. 4C), IL-6 (Fig. 4D), and MCP-1 (Fig. 4E) were raised
3.3 ± 1.0, 4.8± 1.0, and 7.9± 4.3-fold in ATGL deﬁciency, respectively.
NOX2 was upregulated at both mRNA and protein level (Fig. 4F).Additionally, protein expression of cytosolic NADPH oxidase subunits
p67phox and p47phox (Fig. 4G) which initiate NOX2 activation, was sig-
niﬁcantly increased. Expression of Mac-2 protein was potently upregu-
lated in PVAT of AKO mice (Fig. 4H), indicating massive inﬁltration of
macrophages into PVAT. SOD-1 was signiﬁcantly reduced at both
mRNA (data not shown) and protein level (Fig. 4I) and H2O2 release
from PVAT showed a tendency to increase in ATGL deﬁciency, but re-
sults did not reach statistical signiﬁcance (Fig. 4J). mRNA expression of
the stress response marker HO-1 was increased 5.6 ± 1.2-fold in
PVAT of AKOmice (Fig. 4K). Similar to the results obtainedwith isolated
aortas, protein expression and phosphorylation of eNOS were signiﬁ-
cantly reduced in PVAT of AKO mice (Fig. 4L). Representative Western
blots are shown in Fig. 4M and N. To test if the observed phenotype is
related to cardiac dysfunction, PVAT of Wy 14,643-fed WT and AKO
mice was analyzed for selected parameters of oxidative and inﬂamma-
tory stress. Treatment of animals with the PPARα agonist failed to
reverse Mac-2, SOD-1, and p67phox protein expression (Fig. S2), sug-
gesting that heart-independent pathological processes are operative in
PVAT of AKO mice.
To judge potential functional consequences of PVAT-derived inﬂam-
matory oxidative stress we measured contractile and relaxant re-
sponses of aortas isolated from WT and AKO mice in the absence and
presence of PVAT. As shown in Fig. 5A, vascular contractility to K+
was similar for all experimental groups. Fig. 5B illustrates the contractile
responses of WT and AKO aortas to the thromboxane mimetic U46619.
Fig. 4. Characterization of ATGL-deﬁcient PVAT. (A, B) The amount of PVAT surrounding thoracic aortas was substantially increased in AKO mice; *P b 0.05 vsWT; n = 30–32. Adipose
mRNA expression of (C) TNFα (n = 15), (D) IL-6 (n = 10–11), and (E) MCP-1 (n = 15) was increased in ATGL-deﬁcient PVAT; *P b 0.05 vsWT. (F) mRNA and protein expression of
NOX2was upregulated in PVAT of AKOmice; *P b 0.05 vsWT; n= 16–18. (G) Protein expression of NOX2-related p47phox (n= 16–17) and p67phox (n= 9–10) subunits was increased;
*P b 0.05 vsWT. (H) Protein expression of Mac-2 was highly upregulated; *P b 0.05 vsWT; n= 6–9. (I) SOD-1 protein was downregulated in PVAT of AKOmice; *P b 0.05 vsWT; n= 9.
(J) Catalase-inhibited H2O2 release from PVAT; n= 7. (K) Adipose mRNA levels of HO-1 were upregulated in ATGL deﬁciency; *P b 0.05 vsWT; n= 7–9. (L) Protein expression and phos-
phorylation of eNOSwere downregulated in PVAT of AKOmice; *P b 0.05 vsWT; n= 6–17. Protein andmRNA expression is presented relative toWT controls (=1). Data representmean
values ± SEM of n experiments.
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mental groups. Presence of PVAT, however, signiﬁcantly reduced the
contractile efﬁcacy of U46619 in WT aortas (from 155.1 ± 5.7% to
125.6 ± 9.4%). An even more pronounced effect of PVAT was observed
in AKO aortas, with PVAT reducing maximal contractility from 162.9 ±
5.5% to 90.4 ± 9.6%. In contrast to its effects on vascular contractility,
PVAT did not affect relaxation to ACh or DEA/NO under any experimen-
tal condition (Fig. 5C, D).
4.5. Studies on vessel layer morphology and endothelial integrity
Histological analysis of aortic sections obtained from WT and AKO
mice that were stained with H&E showed no microscopic changes in
vessel structure or layer morphology (Fig. 6). Labeling of aorticspecimens for the endothelial and smooth muscle cell markers CD31
and α-SMA, respectively, revealed similar staining distribution and in-
tensity, excluding prominent histological differences of endothelial
and smooth muscle cell layers (Fig. 6). To test for integrity of the vascu-
lar endothelium, the luminalmorphology of aortaswas studied by scan-
ning electronmicroscopy. In Fig. 7, aortic endothelia ofWT (A) and AKO
(B) mice are shown in smaller (left panel) and larger (right panel)
magniﬁcation. Layers of both experimental groups exhibited slightly
undulating longitudinal endothelial folds. Endothelial cells ofWT aortas
showed rhomboid to slender longish shapes with a length of 45–60 μm
and a width of 7–12 μm (Fig. 7A, right panel). Cell borders were rather
straight with no prominent overlapping of neighboring cells. The endo-
thelial luminal surface of AKO aortas is illustrated in Fig. 7B. Most of en-
dothelial cells were rather stout with a length of 25 μm and a width of
Fig. 5. Effect of PVATon vessel function. (A) Aortas isolated fromWTandAKOmice exhibited comparable contractility to K+ in the absence and presence of PVAT; n=4–5. (B) Presence of
PVAT reduced the contractile efﬁcacy of U46619 in aortas of AKO mice to a greater extent than inWT mice; *P b 0.05 vs PVAT-denuded WT; §P b 0.05 vs PVAT-containingWT; n = 4–5.
Relaxation to (C) ACh and (D) DEA/NO was not affected by PVAT; n = 4–5. Data represent mean values ± SEM of n individual experiments.
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served. Endothelia of both experimental groups revealed endothelial fe-
nestrae with variations in number and size. Based on these results, we
have no experimental evidence for disturbances in the microstructural
integrity of the endothelial cell barrier.
5. Discussion
This study demonstrates that AKO mice, a rodent model of NLSDM,
suffer from severe micro- and macrovascular endothelial dysfunction.
Loss of vascular reactivity was partially rescued in AKOmice chronically
treatedwith a PPARα agonist, that restored cardiac function of these an-
imals [2] without exerting direct vasoprotective effects. This suggests
that at least two mechanism (one of which is apparently heart-
dependent) are operative in endothelial dysfunction.
One component comprises downregulation of eNOS expression in
blood vessels. The close relationship between cardiac and vascular dys-
function is well-documented in experimental animals and human sur-
veys (for review, see [4]) and might therefore also exist in AKO mice.
Moreover, experimentally-provoked chronic heart failure was reported
to result in endothelial dysfunction due to downregulation of vascular
eNOS transcription [28]. However, in AKO mice, eNOS mRNA levels
were not decreased but rather tended to slightly increase which ex-
cludes a transcriptional effect. It has been reported that TNFα causes a
substantial decrease in eNOS mRNA stability [29], and TNFαmRNA ex-
pression is indeed increased in several tissues of AKO mice (this study
[30]). Since plasma TNFα levels were beyond the detection limit of the
assay in both experimental groups (data not shown), we cannot judgethe contribution of circulating TNFα to vascular eNOS downregulation.
However, our data point to an alternative explanation involving
proteasomal degradation of eNOS protein in AKO vessels. It has been re-
ported recently that selective inhibition of the 26S proteasome caused
upregulation of eNOS in cultured endothelial cells and improved
endothelial function of isolated aortas [25]. This ﬁnding agrees well
with our observations showing the inverse effect i.e. decreased eNOS
protein expression in AKO vessels accompanied by a signiﬁcant loss of
ubiquitinated proteins indicating enhanced proteasomal activity. More-
over, the proteasomal 20S core subunit (which comprises the protease-
like catalytic sites of the 26S proteasome machinery) was signiﬁcantly
upregulated in vessels of AKO mice.
So far, we have been unable to identify the mediator(s) that trig-
ger(s) upregulation/activation of the proteasome in ATGL-deﬁcient
blood vessels. An obvious culprit that should be considered is oxidative
stress. It has been proposed that mild oxidative challenge leads to
activation of the 26S proteasome by as yet unknown mechanisms (for
review, see [31]). In contrast, prolonged exposure of cells to severe ox-
idative stress is thought to induce de novo biosynthesis of proteasomal
proteins and their assembly to functional degradating units in order to
cope with accumulating misfolded proteins (for review, see [31]). Our
observation that AKO mice suffer from pronounced NADPH oxidase-
driven oxidative stress in the heart supports this hypothesis [30]. More-
over, the fact, that the 20S core protein was signiﬁcantly upregulated in
AKO aortas, strengthens this concept. However, endothelial function
was not improved upon preincubation of ATGL-deﬁcient rings with ei-
ther SOD/cat or the NADPH oxidase-speciﬁc inhibitor gp91ds-dat,
questioning a signiﬁcant contribution of NADPH oxidase-derived
Fig. 6. Histological characterization of WT and AKO aortas. Representative images of WT and AKO specimens stained with H&E showed nomorphological changes through all sections of
the aorta (upper panels). Endothelial cells labeledwith CD31 (middle panel) or smoothmuscle cells labeledwithα-SMA (lower panel) exhibit similar staining intensity and distribution in
sections of WT and AKO aortas. Images are representative for 3 individual experiments.
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oxidative stress may cause irreversible damage of the endothelium,
precluding effects of short-term interventions.
To investigate if endothelial dysfunction originates from disturbed
endothelial cell homeostasis we studied the effects of ATGL deﬁciency
on NO signaling in a microvascular endothelial cell model. Cells obtain-
ed fromWTmice expressed small amounts of functionally active ATGL,
but the biochemical parameters of NO signaling were identical in ATGL-
deﬁcient cells. In particular, the eNOS expression level was not affected
by ATGL deﬁciency, indicating that proteasomal activation in the vascu-
lature is not caused by an intrinsic endothelial process. To test for a po-
tential role of circulating factors thatmight bemissing in the cell culture
model, we challenged WT endothelial cells for 48 h with plasma from
AKOmice but did not observe any effect on eNOS activity (Mussbacher
M; unpublished observation).
Phosphorylation of the protein kinase G target VASP was virtually
abolished in ATGL-deﬁcient blood vessels. This ﬁnding agrees well
with the relaxation data and impressively demonstrates impaired NO
signaling in this pathology. Surprisingly, however, the VASP protein
was also signiﬁcantly downregulated in AKOaortas. VASPplays a crucial
role in the regulation of actin ﬁlament dynamics and is regulated by dif-
ferential phosphorylation [32]. Endothelial VASP deﬁciency was found
to result in compromised integrin- and cadherin-mediated cytoskeletal
anchorage [33]. Therefore, we reasoned that reduced VASP expression
in ATGL-deﬁcient aortas might result in compromised integrity of
the endothelial cell layer. However, scanning electron microscopicexperiments revealed comparable integrity of aortic endothelia. Thus,
loss of aortic VASP protein appears to be a consequence rather than a
cause of endothelial dysfunction andmay reﬂect enhanced proteasomal
activity of ATGL-deﬁcient aortas.
PVAT represents another potential source of pathogenic mediators
that provoke endothelial dysfunction. Inﬂammation and oxidative
stress in PVAT have recently been linked to endothelial dysfunction in
obese experimental animals and adipose humans [34–36]. In particular,
it has been suggested that oxidative and inﬂammatory mediators blunt
the anti-contractile effect of PVAT that is generally regarded as beneﬁ-
cial physiological contribution to vascular tone [34]. In AKOmice, aortic
PVAT mass was drastically increased. Moreover, we observed pro-
nounced upregulation of NADPH oxidases and several inﬂammatory
markers. Upregulation of HO-1 mRNA expression together with re-
duced SOD-1 mRNA and protein abundance are further indicators of a
pro-oxidative scenario in PVAT of AKO mice. Upregulation of Mac-2
protein, a lectin that is expressed and secreted by macrophages and
monocytes [37] and that induces chemotactic, phagocytic, and lipid
scavengingprocesses [38–40] points to severe chronic adipose tissue in-
ﬂammation. The fact that Wy 14,643 treatment failed to protect AKO
mice from PVAT inﬂammation suggests that heart-independent patho-
logical processes are operative in PVAT of AKO mice.
In functional studies, contraction of WT and AKO aortas to the
thromboxane mimetic U46619 was identical in the absence of PVAT.
However, PVAT-coated vessels of AKO mice surprisingly showed a sig-
niﬁcantly attenuated response as compared to WT. In previous studies,
Fig. 7. Scanning electron microscopy of the luminal endothelial surface morphology. Experiments conﬁrm the endothelial integrity of thoracic aorta inWT (A) and AKO (B) mice. Arrows
point to round endothelial fenestrae, arrowheads to protruding endothelial cell nuclei. Asterisks mark oriﬁces of abutting intercostal arteries. EC; endothelial cell; horizontal ﬁeld width:
(A) 1.20 mm (left), 110 μm (right); (B) 1.95 mm (left), 60 μm (right). Images are representative for 3 individual experiments.
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interpreted as beneﬁcial effect and efforts have been made to identify
the adipose tissue-derived relaxing factor [41–43]. Our results differ
from those of a recent study showing that attenuated contractility in
the presence of PVAT is abolished in amousemodel of humanmetabolic
syndrome [36]. The apparent discrepancymay arise from a quite differ-
entmetabolic proﬁle of the experimental animals used.While AKOmice
show increased insulin sensitivity, improved glucose uptake and utiliza-
tion, and physiological serum triglycerides [1], classical animal models
of obesity are characterized by hyperglycemia, hyperinsulinemia, and
increased serum triglycerides [35,36]. It is therefore conceivable, that
signiﬁcant differences in perivascular adipocyte and/or vascular smooth
muscle cell metabolism lead to opposite functional effects of PVAT.
In summary,wedemonstrate that global ATGL deﬁciency leads to pro-
nounced vascular endothelial dysfunctionwhich is partially due to down-
regulation of vascular eNOS expression, presumably via upregulation/
activation of the 26S proteasome. Moreover, we have demonstrated
local PVAT inﬂammation in AKO mice. More work is needed to clarify
the molecular mechanisms behind these unexpected ﬁndings and to
further characterize the local vascular inﬂammatory processes that
might compromise endothelial function. Our results reveal a hitherto
unrecognized link between disturbed lipid metabolism, obesity and
cardiovascular disease.
Murine ATGL deﬁciency is regarded as rodent pendant of NLSDM in
humans. This rare genetic disorder is characterized by excessive lipid
accumulation in multiple tissues and becomes clinically evident most
notably as severe dilated cardiomyopathy. To our current knowledge,
vascular function of these patients has not been studied, yet. On the
basis of the results we obtained with AKO mice it seems obvious that
characterization of vessel function of diseased humans should be in-
cluded into clinical studies.
Supplementary data to this article can be found online at http://dx.
doi.org/10.1016/j.bbalip.2014.03.005.Acknowledgements
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